6.47
-5.27%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Instil Bio
From its filings with the US Securities and Exchange Commission
Instil Bio is based in Dallas, Texas and is incorporated in New York. Its shares trade on Nasdaq under the ticker TIL. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2021, it reported revenue of $0.
We are a biotechnology company focused on identifying and advancing innovative therapeutic opportunities.
In January 2026 we announced our wholly owned subsidiary, Axion Bio, Inc., or Axion Bio, was discontinuing development of our former lead product candidate, AXN-2510, a bispecific antibody targeting both programmed death-ligand 1 and the family of vascular endothelial growth factors in solid tumor cancers. Axion Bio in-licensed AXN-2510 from ImmuneOnco Biopharmaceuticals (Shanghai) Inc., or ImmuneOnco, in August 2024. The license and collaboration agreement with ImmuneOnco was terminated in January 2026. Prior to developing AXN-2510, our development efforts were focused on pursuing the development of cell therapies, including our proprietary folate receptor alpha co-stimulatory antigen receptor (CoStAR) tumor infiltrating lymphocyte (TIL) cell therapy for the treatment of cancer.
We are actively seeking to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.
Our strategy is to pursue potential acquisitions or in-licensing of therapeutic candidates.
Quoted from its 10-K, filed 27 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 19 Mar 2021
- Employees
- 150
- Website
- instilbio.com ↗
- Head office
- 3963 MAPLE AVENUE, DALLAS, TX, 75219
- Incorporated in
- NY
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Bronson CrouchChairman of the Board, Chief Executive Officer, since 2018$5.3m
- Dr. Sandeep LaumasChief Financial Officer, Chief Business Officer$4.1m
- Dr. Neil GibsonLead Independent Director$74,715
- Dr. Gwendolyn Binder-SchollIndependent Director$79,715
- Dr. George MatchamIndependent Director$82,465
- Mr. R. Kent McgaughyIndependent Director$94,090
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 33
- Social
- 61
- Governance
- 7
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is headquartered in Dallas, Texas with 150 employees.
- Company has an IPO date of 2021-03-19.
- Company focuses on developing cell therapy pipeline of autologous TIL therapies for cancer treatment.
Weaknesses
- Sector and industry are listed as N/A in the provided information.
- Company is described as clinical-stage biopharmaceutical with no specific product approval mentioned.
- Company's pipeline includes products in development without current market presence.
Opportunities
- Company is advancing ITIL-168 for advanced melanoma treatment.
- Company is developing CoStAR-TIL therapies targeting multiple solid tumors including ovarian and uterine cancer.
- Company's CoStAR platform enables genetically engineered TIL therapies for various cancer types.
Threats
- Company operates in a clinical-stage biopharmaceutical sector with inherent development risks.
- No specific market approval or commercialization status is provided for any product.
- Company's focus on cancer treatment faces competition in the biopharmaceutical industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.